Nordic Pharma Group   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Paris France (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2011
NCT01446211
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Nordic Pharma SAS | Nordic Pharma, USA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 2)

Granulomatosis with Polyangiitis (Phase 3)

Hyperlipidemia, Familial Combined (Phase 4)

Hyperlipidemias (Phase 4)

Hyperlipoproteinemias (Phase 4)

Hyperlipoproteinemia Type V (Phase 4)

Lipidoses (Phase 4)

Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 12